Literature DB >> 26340986

Cyclophosphamide plus granulocyte-colony stimulating factor for hematopoietic stem cell mobilization in patients with multiple myeloma.

Tung-Liang Lin1, Po-Nan Wang2, Ming-Chung Kuo1,3, Yu-Hsing Hung1, Hung Chang1,3, Tzung-Chih Tang1,3.   

Abstract

We retrospectively reviewed the results of cyclophosphamide (3 g/m(2) ), doxorubicin and dexamethasone plus granulocyte-colony stimulating factor (G-CSF) (ID-CY/DOX group), low-dose cyclophosphamide (2 g/m(2) ) plus G-CSF (LD-CY group) and G-CSF alone (G-CSF group) for stem cell mobilization in patients with multiple myeloma. A total of 89 patients with 93 mobilizations were included. Apheresis was started when total white blood cell (WBC) count >10 × 10(9) /L for ID-CY/DOX and LD-CY groups and after eight doses of G-CSF (5 μg/kg twice daily) for G-CSF group. For five mobilizations in ID-CY/DOX group, the rate of successful mobilization (≥4.0 × 10(6) /kg CD34+ cells) was 80%. For 78 mobilizations in LD-CY group, the successful rate was 80.8%. For 10 mobilizations in the G-CSF group, the successful rate was 50%. The mean yield of CD34+ cells was higher in ID-CY/DOX and LD-CY groups as compared with that in G-CSF group (P = 0.026 and 0.020, respectively). There was no difference in the yield of CD34+ cells between ID-CY/DOX and LD-CY groups (P = 0.831). After autologous stem cell transplantation, the days to neutrophil and platelet engraftment were similar in these three groups (P = 0.713 and 0.821, respectively). In conclusion, we observed that ID-CY/DOX and LD-CY plus G-CSF for stem cell mobilization resulted in a higher successful rate and higher stem cell yields than G-CSF alone and their engraftment time were similar. Total WBC count >10 × 10(9) /L can be used as a guide to start apheresis in CY-based stem cell mobilization. J. Clin. Apheresis 31:423-428, 2016.
© 2015 Wiley Periodicals, Inc. © 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  autologous hematopoietic stem cell transplantation; cyclophosphamide; granulocyte-colony stimulating factor; hematopoietic stem cell mobilization; multiple myeloma

Mesh:

Substances:

Year:  2015        PMID: 26340986     DOI: 10.1002/jca.21421

Source DB:  PubMed          Journal:  J Clin Apher        ISSN: 0733-2459            Impact factor:   2.821


  6 in total

1.  The association of mobilising regimen on immune reconstitution and survival in myeloma patients treated with bortezomib, cyclophosphamide and dexamethasone induction followed by a melphalan autograft.

Authors:  Matthew J Rees; Peter Mollee; Jun Yen Ng; Alex Murton; Jose Filipe Gonsalves; Ashish Panigrahi; Hayley Beer; Joanna Loh; Philip Nguyen; Sam Hunt; Hayden Jina; Rebecca Wayte; Gaurav Sutrave; Jocelyn Tan; Chathuri Abeyakoon; Ashlyn Chee; Bradley Augustson; Akash Kalro; Cindy Lee; Shivam Agrawal; Leonid Churilov; Chong Chyn Chua; Andrew Boon Ming Lim; Daniela Zantomio; Andrew Grigg
Journal:  Bone Marrow Transplant       Date:  2021-04-28       Impact factor: 5.483

2.  Autologous stem cell transplant for multiple myeloma patients 70 years or older.

Authors:  E Muchtar; D Dingli; S Kumar; F K Buadi; A Dispenzieri; S R Hayman; R C Wolf; D A Gastineau; R Chakraborty; W J Hogan; N Leung; P Kapoor; M Q Lacy; S V Rajkumar; M A Gertz
Journal:  Bone Marrow Transplant       Date:  2016-07-04       Impact factor: 5.483

3.  [Effect of cyclophosphamide on hematopoietic stem cells in mice with iron overload].

Authors:  Yanjun Xu; Tiantian Yi; Xiaoxiao Xu; Fuyu Pei; Yuelin He; Xuedong Wu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2020-01-30

4.  Comparison of the efficiency, safety, and survival outcomes in two stem cell mobilization regimens with cyclophosphamide plus G-CSF or G-CSF alone in multiple myeloma: a meta-analysis.

Authors:  Liwen Wang; Hongxian Xiang; Yuhan Yan; Zuqun Deng; Hui Li; Xin Li; Jin Liu
Journal:  Ann Hematol       Date:  2021-01-06       Impact factor: 3.673

5.  The Efficacy and Safety of Chemotherapy-Based Stem Cell Mobilization in Multiple Myeloma Patients Who Are Poor Responders to Induction: The Mayo Clinic Experience.

Authors:  Iuliana Vaxman; Eli Muchtar; Eapen Jacob; Prashant Kapoor; Shaji Kumar; Angela Dispenzieri; Francis Buadi; David Dingli; Wilson Gonsalves; Taxiarchis Kourelis; Rahma Warsame; Martha Lacy; William Hogan; Morie A Gertz
Journal:  Transplant Cell Ther       Date:  2021-06-18

Review 6.  Getting blood out of a stone: Identification and management of patients with poor hematopoietic cell mobilization.

Authors:  Jian Chen; Hillard M Lazarus; Parastoo B Dahi; Scott Avecilla; Sergio A Giralt
Journal:  Blood Rev       Date:  2020-10-31       Impact factor: 10.626

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.